BMS Oral Kinase Inhibitor Inrebic Approved by UK NICE for Myelofibrosis

Compilenewborn

The UK National Institute for Health and Clinical Excellence (NICE) recently issued a final assessment decision (FAD) recommending the use of Bristol-Myers Squibb's oral kinase inhibitor Inrebic (fedratinib) in the NHS for the treatment of bone marrow Fibrosis, a rare blood cancer that affects the bone marrow and disrupts the production of blood cells in the body

Symptoms of myelofibrosis are often debilitating and include fatigue, itching, weight loss, night sweats, fever, bone pain, and an enlarged spleen

Inrebic is recommended under the Cancer Drugs Fund (CDF) category for primary myelofibrosis, post-polycythemia vera myelofibrosis, and essential thrombocythemia previously treated with ruxolitinib In adult patients with post-myelofibrosis, treat disease-related splenomegaly or symptoms

Claire N.

Inrebic's active pharmaceutical ingredient is fedratinib, an oral kinase inhibitor with activity against wild-type and mutant-activated Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3)

Inrebic was obtained from Bristol-Myers Squibb's US$74 billion acquisition of Celgene.

Reference source: NICE recommends Inrebic for rare blood cancer